Thanks for your feedback, this will help us improve our content for you!
Thank for your feedback, this will help us improve our content for you!
Speaking from the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany, Georg Fey, PhD, of the University of Erlangen Nuremberg, Erlangen and Nuremberg, Germany, explains the benefits of dual-targeting triplebodies.
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest hemonc news and updates
Keep up to date with all the latest news with our monthly newsletter